Evidence map›Paper›PMID 36814257›Full record

ReviewEnvironmental health : a global access science source2023

Consideration of pathways for immunotoxicity of per- and polyfluoroalkyl substances (PFAS).

Veronika Ehrlich, Wieneke Bil, Rob Vandebriel, Berit Granum, Mirjam Luijten, Birgitte Lindeman, Philippe Grandjean, Andreas-Marius Kaiser, Ingrid Hauzenberger, Christina Hartmann and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in Environmental health : a global access science source, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed, 2 pooled it
35.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 2 syntheses or guidelines pooled it, 251 citations in OpenAlex.

  1. Pooled it
  2. Per- and poly-fluoroalkyl substances exposure and risk of gastrointestinal cancers: a systematic review and meta-analysis.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2025
    Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Observational
  20. Article

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 5 countries.

Veronika EhrlichEnvironment Agency Austria (Umweltbundesamt GmbH), Spittelauer Lände 5, 1090, Vienna, Austria.
Wieneke BilCentre for Safety of Substances and Products, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Rob VandebrielCentre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Berit GranumDivision of Climate and Environment Health, Norwegian Institute of Public Health, Oslo, Norway.
Mirjam LuijtenCentre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Birgitte LindemanDivision of Climate and Environment Health, Norwegian Institute of Public Health, Oslo, Norway.
Philippe GrandjeanDepartment of Public Health, University of Southern Denmark, Odense, Denmark.
Andreas-Marius KaiserEnvironment Agency Austria (Umweltbundesamt GmbH), Spittelauer Lände 5, 1090, Vienna, Austria.
Ingrid HauzenbergerEnvironment Agency Austria (Umweltbundesamt GmbH), Spittelauer Lände 5, 1090, Vienna, Austria.
Christina HartmannEnvironment Agency Austria (Umweltbundesamt GmbH), Spittelauer Lände 5, 1090, Vienna, Austria.
Claudia GundackerCenter for Pathobiochemistry and Genetics, Medical University of Vienna, Vienna, Austria.
Maria UhlEnvironment Agency Austria (Umweltbundesamt GmbH), Spittelauer Lände 5, 1090, Vienna, Austria. maria.uhl@umweltbundesamt.at.
Environment Agency Austria · ATNational Institute for Public Health and the Environment · NLNorwegian Institute of Public Health · NOMedical University of Vienna · ATUniversity of Rhode Island · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPer- and polyfluoroalkyl substances (PFAS) are of public health concern, because of their ubiquitous and extremely persistent occurrence, and depending on their structure, their bio-accumulative, mobile and toxic properties. Human health effects associated with exposure to PFAS include adverse effects on the immune system. In 2020, EFSA (the European Food Safety Authority) defined adverse effects on the immune system as the most critical effect for human health risk assessment, based on reduced antibody responses to childhood vaccines and similar effects observed in experimental animal studies. Likewise, the U.S. EPA (Environmental Protection Agency) considers PFAS-induced immunotoxicity, especially in children, as the critical effect for risk assessment. However, the mechanisms by which antibody concentrations are impacted are not completely understood. Furthermore, other targets of the immune system functions have been reported in the literature.

objectiveThe aim of this review is to explore PFAS-associated immune-related effects. This includes, relevant mechanisms that may underlie the observed effects on the immune system, immunosuppression as well as immunoenhancement, such as i) modulation of cell signalling and nuclear receptors, such as NF-κB and PPARs; ii) alteration of calcium signalling and homoeostasis in immune cells; iii) modulation of immune cell populations; iv) oxidative stress and v) impact on fatty acid metabolism & secondary effects on the immune system.

methodsA literature research was conducted using three databases (Web of Science, PubMed, and Scopus), which were searched in July 2021 for relevant studies published in the time frame from 2018 to 2021. In total, 487 publications were identified as potentially eligible and following expert-based judgement, articles relevant for mechanisms of PFAS induced immunotoxicity are discussed.

conclusionsTaken together, we show that there is substantial evidence from both in vitro and in vivo experimental as well as epidemiological studies, supporting that various PFAS, not only PFOA and PFOS, affect multiple aspects of the immune system. Timing of exposure is critical, because the developing immune system is especially vulnerable to toxic insults, resulting in a higher risk of particularly adverse immune effects but also other organs later in life.

Indexed as

Alkanesulfonic AcidsEnvironmental PollutantsFluorocarbonsAnimalsChildHumansOxidative StressPublic HealthRisk AssessmentAlkanesulfonic AcidsEnvironmental PollutantsFluorocarbonsHBM4EUImmune functionImmunotoxicityMolecular mechanismsPer- and polyfluoroalkyl substancesVaccination response

Identifiers

PMID36814257
PMCPMC9944481
OpenAlexW4321498246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.